Patents by Inventor Janek Szychowski

Janek Szychowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • QUINAZOLINONES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME
    Publication number: 20230348456
    Abstract: Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.
    Type: Application
    Filed: April 27, 2023
    Publication date: November 2, 2023
    Applicant: Repare Therapeutics Inc.
    Inventors: Janek SZYCHOWSKI, Bingcan LIU, Evelyne DIETRICH, Alexander PERRYMAN, Sheldon N. CRANE, Vouy Linh TRUONG, Abbas ABDOLI, Alexanne BOUCHARD
  • METHODS OF USING MYT1 INHIBITORS
    Publication number: 20230158022
    Abstract: Disclosed are methods of using inhibitors of tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1), e.g., in the treatment of subjects in need thereof.
    Type: Application
    Filed: April 1, 2021
    Publication date: May 25, 2023
    Inventors: Daniel DUROCHER, Jordan YOUNG, Frank SICHERI, Janek SZYCHOWSKI, Bingcan LIU, Evelyne DIETRICH, Frédéric VALLÉE, Alexander PERRYMAN, Jean-François TRUCHON, Robert PAPP, Theresa ZHANG, Artur VELOSO, Jimmy FOURTOUNIS, Patrick BEAULIEU
  • COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE
    Publication number: 20230151014
    Abstract: Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.
    Type: Application
    Filed: April 1, 2021
    Publication date: May 18, 2023
    Inventors: Janek SZYCHOWSKI, Bingcan LIU, Evelyne DIETRICH, Frédéric VALLÉE, Alexander PERRYMAN, Jean-François TRUCHON, Robert PAPP, Patrick BEAULIEU
  • TRICYCLIC HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME
    Publication number: 20230142913
    Abstract: Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.
    Type: Application
    Filed: October 6, 2022
    Publication date: May 11, 2023
    Inventors: Janek SZYCHOWSKI, Evelyne DIETRICH, Frédéric VALLÉE
  • COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE
    Publication number: 20230122909
    Abstract: Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.
    Type: Application
    Filed: October 4, 2022
    Publication date: April 20, 2023
    Inventors: Janek SZYCHOWSKI, Bingcan LIU, Evelyne DIETRICH, Frédéric VALLÉE, Alexander PERRYMAN, Jean-François TRUCHON, Robert PAPP, Patrick BEAULIEU, Vouy Linh TRUONG, Kaveh MATINKHOO, Sheldon N. CRANE
  • IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY
    Publication number: 20190119282
    Abstract: The present invention relates to compounds useful as inhibitors of the PAR-2 signaling pathway. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of GPCRs in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such GPCRs; and the comparative evaluation of new inhibitors of the PAR-2 signaling pathway. The compounds of this invention have formula I: wherein the variables are as defined herein.
    Type: Application
    Filed: June 20, 2018
    Publication date: April 25, 2019
    Inventors: Luc J. Farmer, Pierre-Andre Fournier, Stephanie Lessard, Bingcan Liu, Miguel St-Onge, Claudio Sturino, Janek Szychowski, Constantin Yannopoulos, Frederic Vallee, Jean-Eric Lacoste, Julien Martel, Monica Bubenik, Yeeman Ramtohul, Camil Elie Sayegh
  • Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway
    Patent number: 10030024
    Abstract: The present invention relates to compounds useful as inhibitors of the PAR-2 signaling pathway. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of GPCRs in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such GPCRs; and the comparative evaluation of new inhibitors of the PAR-2 signaling pathway. The compounds of this invention have formula I: wherein the variables are as defined herein.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: July 24, 2018
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Luc J. Farmer, Pierre-Andre Fournier, Stephanie Lessard, Bingcan Liu, Miguel St-Onge, Claudio Sturino, Janek Szychowski, Constantin Yannopoulos, Frederic Vallee, Jean-Eric Lacoste, Julien Martel, Monica Bubenik, Yeeman Ramtohul, Camil Elie Sayegh
  • BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY
    Publication number: 20180057505
    Abstract: The compounds of formula I, wherein the variables are as defined herein, and pharmaceutically acceptable salts thereof are useful as inhibitors of the PAR-2 signaling pathway. The compounds of formula I and pharmaceutically acceptable compositions comprising such compounds can be employed for treating various diseases, disorders, and conditions.
    Type: Application
    Filed: March 19, 2016
    Publication date: March 1, 2018
    Inventors: Camil Elie SAYEGH, Claudio STURINO, Pierre-Andre FOURNIER, Jean-Eric LACOSTE, Evelyne DIETRICH, Julien MARTEL, Frederic VALLEE, Janek SZYCHOWSKI, Miguel ST-ONGE, Monica BUBENIK, Stephanie LESSARD, Yeeman RAMTOHUL
  • IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY
    Publication number: 20160311825
    Abstract: The present invention relates to compounds useful as inhibitors of the PAR-2 signaling pathway. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of GPCRs in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such GPCRs; and the comparative evaluation of new inhibitors of the PAR-2 signaling pathway. The compounds of this invention have formula I: wherein the variables are as defined herein.
    Type: Application
    Filed: March 25, 2016
    Publication date: October 27, 2016
    Inventors: Luc J. Farmer, Pierre-Andre Fournier, Stephanie Lessard, Bingcan Liu, Miguel St-Onge, Claudio Sturino, Janek Szychowski, Constantin Yannopoulos, Frederic Vallee, Jean-Eric Lacoste, Julien Martel, Monica Bubenik, Yeeman Ramtohul, Camil Elie Sayegh
  • Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents
    Patent number: 8569264
    Abstract: The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
    Type: Grant
    Filed: January 5, 2012
    Date of Patent: October 29, 2013
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Stephen Hanessian, Janek Szychowski, Susanta Sekhar Adhikari, Kandasamy Pachamuthu, Xiaojing Wang, Michael T. Migawa, Richard H. Griffey
  • ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS
    Publication number: 20130005674
    Abstract: The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
    Type: Application
    Filed: January 5, 2012
    Publication date: January 3, 2013
    Applicant: ISIS Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Stephen Hanessian, Janek Szychowski, Susanta Sekhar Adhikari, Kandasamy Pachamuthu, Xiaojing Wang, Michael T. Migawa, Richard H. Griffey
  • METHODS AND SYSTEMS ASSOCIATED WITH DETECTION OF FATTY ACID ELONGATION IN A CELL
    Publication number: 20120231470
    Abstract: Methods and systems to identify compounds capable of altering a fatty acid elongation pathway and for identifying conditions under which fatty acids elongation can occur in a cell are described. The methods and systems comprise labeled fatty acid precursors and cells capable of elongating fatty acids. Methods for providing suitable components of an assay for identifying compounds capable of altering a fatty acid elongation pathway are described.
    Type: Application
    Filed: March 7, 2012
    Publication date: September 13, 2012
    Inventors: Janek SZYCHOWSKI, David A. TIRRELL, Sungjin Park
  • Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents
    Patent number: 8114856
    Abstract: The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
    Type: Grant
    Filed: January 10, 2011
    Date of Patent: February 14, 2012
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Stephen Hanessian, Janek Szychowski, Susanta Sekhar Adhikari, Kandasamy Pachamuthu, Xiaojing Wang, Michael T. Migawa, Richard H. Griffey
  • ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS
    Publication number: 20110166334
    Abstract: The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
    Type: Application
    Filed: January 10, 2011
    Publication date: July 7, 2011
    Applicant: ISIS Pharmaceuticals,Inc.
    Inventors: Eric E. Swayze, Stephen Hanessian, Janek Szychowski, Susanta Sekhar Adhikari, Kandasamy Pachamuthu, Xiaojing Wang, Michael T. Migawa, Richard H. Griffey
  • Antimicrobial 2-deoxystreptamine compounds
    Patent number: 7943749
    Abstract: The present invention is directed to analogs of paromomycin having a variety of chemical functional groups attached at the 2?-O-position as well as their preparation and use as prophylactic or therapeutics against microbial infection.
    Type: Grant
    Filed: April 27, 2007
    Date of Patent: May 17, 2011
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Stephen Hanessian, Janek Szychowski, Susanta Sekhar Adhikari, Kandasamy Pachamuthu, Michael T. Migawa, Richard H. Griffey, Eric Swayze
  • Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents
    Patent number: 7893039
    Abstract: The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: February 22, 2011
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Stephen Hanessian, Janek Szychowski, Susanta Sekhar Adhikari, Kandasamy Pachamuthu, Xiaojing Wang, Michael T. Migawa, Richard H. Griffey
  • ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS
    Publication number: 20080293649
    Abstract: The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
    Type: Application
    Filed: May 30, 2008
    Publication date: November 27, 2008
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Eric E. Swayze, Stephen Hanessian, Janek Szychowski, Susanta Sekhar Adhikari, Kandasamy Pachamuthu, Xiaojing Wang, Michael T. Migawa, Richard H. Griffey
  • ANTIMICROBIAL 2-DEOXYSTREPTAMINE COMPOUNDS
    Publication number: 20080045468
    Abstract: The present invention is directed to analogs of paromomycin having a variety of chemical functional groups attached at the 2?-O-position as well as their preparation and use as prophylactic or therapeutics against microbial infection.
    Type: Application
    Filed: April 27, 2007
    Publication date: February 21, 2008
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Stephen Hanessian, Janek Szychowski, Susanta Adhikari, Kandasamy Pachamuthu, Michael Migawa, Richard Griffey, Eric Swayze